The use of biomarkers for the etiologic diagnosis of MCI in Europe: an EADC survey
- Bocchetta, M.
- Galluzzi, S.
- Kehoe, P.G.
- Aguera, E.
- Bernabei, R.
- Bullock, R.
- Ceccaldi, M.
- Dartigues, J.F.
- de Mendonca, A.
- Didic, M.
- Eriksdotter, M.
- Felician, O.
- Froelich, L.
- Gertz, H.J.
- Hallikainen, M.
- Hasselbalch, S.G.
- Hausner, L.
- Heuser, I.
- Jessen, F.
- Jones, R.W.
- Kurz, A.
- Lawlor, B.
- Lleo, A.
- Martinez-Lage, P.
- Mecocci, P.
- Mehrabian, S.
- Monsch, A.
- Nobili, F.
- Nordberg, A.
- Rikkert, M.O.
- Orgogozo, J.M.
- Pasquier, F.
- Peters, O.
- Salmon, E.
- Sanchez-Castellano, C.
- Santana, I.
- Sarazin, M.
- Traykov, L.
- Tsolaki, M.
- Visser, P.J.
- Wallin, A.K.
- Wilcock, G.
- Wilkinson, D.
- Wolf, H.
- Yener, G.
- Zekry, D.
- Frisoni, G.B.
DOIAbstract
We investigated the use of Alzheimer's disease (AD) biomarkers in European Alzheimer's Disease Consortium centers and assessed their perceived usefulness for the etiologic diagnosis of mild cognitive impairment (MCI). We surveyed availability, frequency of use, and confidence in diagnostic usefulness of markers of brain amyloidosis (amyloid positron emission tomography [PET], cerebrospinal fluid [CSF] Abeta42) and neurodegeneration (medial temporal atrophy [MTA] on MR, fluorodeoxyglucose positron emission tomography [FDG-PET], CSF tau). The most frequently used biomarker is visually rated MTA (75% of the 37 responders reported using it "always/frequently") followed by CSF markers (22%), FDG-PET (16%), and amyloid-PET (3%). Only 45% of respo...
Add to ORKG